This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Apr;45(4):1080-1.

doi: 10.1002/hep.21646.

Treatment for cirrhosis-associated hyponatremia? Vaptans and aquaresis

Nicholas Shackel¹, Geoffrey McCaughan

Affiliations

PMID: 17393505
DOI: 10.1002/hep.21646

Comment

Treatment for cirrhosis-associated hyponatremia? Vaptans and aquaresis

Nicholas Shackel et al. Hepatology. 2007 Apr.

. 2007 Apr;45(4):1080-1.

doi: 10.1002/hep.21646.

Authors

Nicholas Shackel¹, Geoffrey McCaughan

Affiliation

¹ Centenary Institute of Cancer, Medicine and Cell Biology, Camperdown, NSW, Australia.

PMID: 17393505
DOI: 10.1002/hep.21646

No abstract available

PubMed Disclaimer

Comment on

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators. Schrier RW, et al. N Engl J Med. 2006 Nov 16;355(20):2099-112. doi: 10.1056/NEJMoa065181. Epub 2006 Nov 14. N Engl J Med. 2006. PMID: 17105757 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley